• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Microbiome Times

Editor's Choice

Researchers Identify Three Distinct Stages in Infant Microbiome Development

October 26, 2018 Microbiome Times

In the largest clinical microbiome study in infants reported to date, a team led by researchers at Baylor College of Medicine explored the sequence of microbial colonization in the infant gut through age 4 and […]

Finance

Microbiotica Attracts Equity Investment from Seventure’s Health for Life Capital™ Fund

October 25, 2018 Microbiome Times

Microbiotica, a leading player in microbiome-based therapeutics, announced that it has attracted an equity investment from Seventure Partners, a leading investor in the microbiome space. This new investment of £4m brings the total equity raised […]

Pharma & Human Health

ConsortiaTX Awarded Exclusive License for Food Allergy Microbial Therapy

October 24, 2018 Microbiome Times

ConsortiaTX, Inc., a bio-therapeutics startup developing and commercializing microbial therapies to prevent and treat human disease and allergies, has signed an agreement with Brigham and Women’s Hospital (BWH) and Boston Children’s Hospital for an exclusive, […]

Animal Health

Gut Bacteria May Play Role in Heart Attack Recovery

October 24, 2018 Microbiome Times

The tiny microbes located inside the intestines could play a critical role in heart attack recovery, according to a new study that found gut bacteria helpful in repairing the damage after a heart attack. But […]

Finance

Enterome Signs Global Licensing, Co-development and Co-promotion Agreement with Takeda for the Treatment of Crohn’s Disease

October 23, 2018 Microbiome Times

ENTEROME SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company […]

Pharma & Human Health

Rebiotix and Microbiome Insights Collaborate on a Microbiome IBD Tool for Clinical Development

October 22, 2018 Microbiome Times

With a growing body of science linking gut microbiota to inflammatory bowel disease (IBD), a need exists in clinical settings to understand changes in the gut microbial community as they relate to IBD and its […]

Finance

Symberix Announces Non-Dilutive Funding Support for Lead Programs

October 22, 2018 Microbiome Times

Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded three Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH), […]

Pharma & Human Health

Wyss Institute Receives Grant from Cystic Fibrosis Foundation

October 18, 2018 Microbiome Times

Patients with cystic fibrosis (CF), a genetic disease that causes a persistent buildup of thick mucus in their lungs and other organs, suffer from chronic bacterial infections and inflammation that often lead to deadly respiratory […]

Pharma & Human Health

LNC Therapeutics Acquires Exclusive License for the Christensenella Patent from Cornell University

October 17, 2018 Microbiome Times

LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery announced that it has signed an exclusive license agreement with Cornell University (Ithaca, NY, USA ) for its Christensenella patent family. Christensenella is a recently […]

Animal Health

Microsoft Genomics Ventures into the Microbiome With Eagle Genomics

October 15, 2018 Microbiome Times

Eagle Genomics announce partnership with Microsoft Genomics, a Microsoft Azure service dedicated to meeting the computational challenges of the genomics era. This is the first Microsoft partner focused in the microbiome genomics market. Microbiomics is […]

Pharma & Human Health

MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD

October 15, 2018 Microbiome Times

MaaT Pharma has announced the dosing of the first patient in a Phase 2 clinical trial of its lead microbiome restoration candidate, MaaT013, in patients with steroid-resistant acute Graft-versus-Host-Disease (SR-aGvHD), the most deadly complication in […]

Posts navigation

« 1 … 61 62 63 … 77 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter